AI/ML Innovations Inc.'s Health Gauge Seeking FDA Approval for Its Patented Blood Pressure Measurement Technology
AI/ML Innovations Inc.'s Health Gauge Seeking FDA Approval for Its Patented Blood Pressure Measurement Technology
Highlights:
亮點:
- FDA 510(k) Class II (Software as a Medical Device) certification commences for the Company's proprietary Blood Pressure Measurement Neural Network.
- The first product release to include the Company's Neural Network is "Follow Your Heart", a consumer wellness wearable smartwatch solution with medical grade accuracy .
- 該公司專有的血壓測量神經網絡的FDA 510(k)二類(軟件即醫療器械)認證開始生效。
- 首款包含公司神經網絡的產品是 “Follow Your Heart”,這是一款具有醫療級精度的消費類健康可穿戴智能手錶解決方案。
VICTORIA, BC / ACCESSWIRE / February 27, 2024 / AI/ML Innovations Inc. (the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to have received the following from its majority-owned subsidiary, Health Gauge Inc.:
不列顛哥倫比亞省維多利亞州/ACCESSWIRE/2024年2月27日/ AI/ML Innovations Inc.(以下簡稱 “公司”)(CSE: AIML)(OTCQB: AIMLF)(FWB: 42FB)是一家致力於收購和推進滿足緊急社會需求的人工智能/機器學習技術的領先公司,很高興從其控股子公司Health Gauge Inc.獲得以下信息:
After an intensive, three-year journey in research and development, the AI and ML Development team at Health Gauge proudly announces the successful training of their advanced Blood Pressure Measurement Neural Network. This achievement marks a pivotal moment, as the Company will now seek FDA (510(k) Class II) Certification for "Software as a Medical Device". Our proprietary technology is poised to advance healthcare outcomes by providing efficient blood pressure measurements in a consumer wearable smartwatch device while delivering unsurpassed accuracy.
經過三年的密集研發之旅,Health Gauge的人工智能和機器學習開發團隊自豪地宣佈,他們的高級血壓測量神經網絡已成功訓練。這一成就標誌着一個關鍵時刻,因爲該公司現在將爲 “軟件即醫療器械” 尋求FDA(510(k)二級)認證。我們的專有技術有望在消費類可穿戴智能手錶設備中提供高效的血壓測量,同時提供無與倫比的準確性,從而改善醫療保健結果。
"Follow Your Heart", a Non-Invasive Blood Pressure Measurement with EdgeAI - Soon to be publicly released, "Follow Your Heart" utilizes the Company's proprietary EdgeAI technology, providing a non-invasive blood pressure measurement through the Company's Smart Sensor Watch, that offers users a convenient, effective health & wellness monitoring solution.
“Follow Your Heart” 是EdgeAI的非侵入性血壓測量——即將公開發布的 “Follow Your Heart” 利用公司的專有EdgeAI技術,通過公司的智能傳感器手錶提供非侵入性血壓測量,爲用戶提供方便、有效的健康和保健監測解決方案。
Randy Duguay, CEO of Health Gauge, stated "We are thrilled that our Neural Net training and validation efforts show that we are able to meet or surpass the FDA requirements as a Class II medical device for blood pressure. In practical terms, this means our wearable is able to perform with a comparable degree of accuracy as a medical grade blood pressure cuff found in your doctor's office, but with the convenience of simply wearing a watch". Duguay continued, "Growth in prevalence of hypertension is a prominent factor driving the global blood pressure cuffs market size. More than 14% of the global population is afflicted with hypertension, which increases the risk of cardiovascular diseases. The global market for blood pressure measurement is expected to grow at a CAGR of 6.5% from 2023 to 2031 and reach US$ 1.0 Bn by the end of 2031. 1 "
Health Gauge首席執行官蘭迪·杜瓜伊表示:“我們很高興我們的神經網絡培訓和驗證工作表明,作爲二類血壓醫療器械,我們能夠達到或超過美國食品藥品管理局的要求。實際上,這意味着我們的可穿戴設備能夠以與醫生辦公室的醫用級血壓袖帶相當的精度運行,但只需佩戴手錶即可”。杜瓜伊繼續說:“高血壓患病率的增長是推動全球血壓袖帶市場規模的重要因素。全球超過14%的人口患有高血壓,這增加了患心血管疾病的風險。預計從2023年到2031年,全球血壓測量市場將以6.5%的複合年增長率增長,到2031年底達到10億美元。 1 “
Paul Duffy, CEO of AI/ML Innovations Inc., added, "Health Gauge's breakthrough in blood pressure measurement technology is a significant leap forward for the health tech industry. We are proud to be associated with a company that continually demonstrates excellence in pushing technological frontiers. This achievement aligns with our collective vision of creating innovative solutions that shape the future of healthcare."
AI/ML Innovations Inc.首席執行官保羅·達菲補充說:“Health Gauge在血壓測量技術方面的突破是健康科技行業向前邁出的重大飛躍。我們很榮幸能與一家在推動技術前沿方面不斷表現出卓越表現的公司合作。這一成就符合我們的集體願景,即創造塑造醫療保健未來的創新解決方案。”
About Health Gauge
關於生命值計
Health Gauge, a majority-owned subsidiary of AI/ML Innovations Inc., is at the forefront of revolutionizing healthcare through the power of Health Intelligence. With a commitment to leveraging technology for human well-being, Health Gauge provides cutting-edge solutions for personalized health insights.
Health Gauge是AI/ML Innovations Inc.的多數股權子公司,站在通過健康情報的力量徹底改變醫療保健的最前沿。Health Gauge致力於利用技術促進人類福祉,爲個性化健康見解提供尖端解決方案。
About AI/ML Innovations Inc.
關於 AI/ML Innovations Inc.
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".
AI/ML Innovations Inc.調整了其業務運營,以利用新興的人工智能(AI)和機器學習(ML)領域,最初的投資重點是新興的數字健康和福祉公司,這些公司利用人工智能、機器學習、雲計算和數字平台推動變革性的醫療管理解決方案和整個健康連續體的精準支持交付。通過與Health Gauge(AIML持有95.2%的股權)、Tech2Heal(高達22%的所有權,目前由AIML持有12.44%的所有權)、AI Rx Inc.(AIML持有70%的股權)以及其他計劃中的增值投資,公司繼續利用不斷擴大的增長領域,使公司所有利益相關者受益。AI/ML的股票在加拿大證券交易所交易,代碼爲 “AIML”,OTCQB風險投資市場以 “AIMLF” 的形式交易,在法蘭克福證券交易所交易的代碼爲 “42FB”。
On behalf of the Board of Directors
代表董事會
Tim Daniels, Executive Chairman
蒂姆·丹尼爾斯,執行主席
For more information about AI/ML Innovations:
有關 AI/ML 創新的更多信息:
For detailed information please see AI/ML's website or the Company's filed documents at
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com
有關詳細信息,請訪問AI/ML的網站或公司的歸檔文件
欲了解更多信息,請致電 (778) 405-0882 或 info@aiml-innovations.com 與 Blake Fallis 聯繫
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
CSE及其監管服務提供商(該術語在CSE的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
For AI/ML Innovations Investors
致人工智能/機器學習創新投資者
Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives, and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at .
本新聞稿中發表的某些非基於歷史信息的陳述是前瞻性陳述,涉及大量已知和未知的風險和不確定性。本新聞稿包含與AI/ML Innovations對管理層計劃、目標和戰略(包括捍衛公司知識產權的戰略)的預期有關的明示或暗示的前瞻性陳述。這些陳述既不是承諾也不是擔保,但存在各種風險和不確定性,其中許多風險和不確定性是我們無法控制的,這可能導致實際結果與這些前瞻性陳述中設想的結果存在重大差異。提醒現有和潛在投資者不要過分依賴這些前瞻性陳述,這些陳述僅代表截至本文發佈之日。除非適用的證券法明確要求,否則AI/ML Innovations Inc. 沒有義務更新或修改本新聞稿中包含的信息,無論是由於新信息、未來事件或情況還是其他原因。有關不確定性和風險的更多信息,可以在AI/ML向證券監管機構提交的披露文件中找到,網址爲。
1
1
SOURCE: AI/ML Innovations Inc.
來源:AI/ML Innovations Inc.